Journal of Clinical Oncology, Vol 14, 1297-1305, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease

A Hirsch, N Vander Els, DJ Straus, EG Gomez, D Leung, CS Portlock and J Yahalom
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY,USA.

PURPOSE: To evaluate the effect of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy alone and of ABVD with mantle or mediastinal irradiation (RT) on the pulmonary function of patients with early-stage Hodgkin's disease. PATIENTS AND METHODS: Between 1989 and 1993, 60 patients with clinical stage I to IIIA HD enrolled onto randomized trials at Memorial Sloan-Kettering Cancer Center (MSKCC) underwent prospective evaluation of pulmonary function. All patients received six cycles of ABVD, and 30 patients received mantle or mediastinal RT. Pulmonary function tests (PFTs) and symptom evaluation were conducted before, during, and after completion of chemotherapy and RT, and at various intervals thereafter. The median follow-up time was 30 months. RESULTS: During chemotherapy, symptoms of cough and dyspnea on exertion developed in 32 of 60 patients (53%) and declines in pulmonary function occurred in 22 of 60 patients (37%). Discontinuation of bleomycin was necessary in 14 of 60 patients (23%). Following chemotherapy, there was a significant decline in median forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO). In patients who received mantle or mediastinal RT, there was a further decline in FVC following radiation therapy. At the most recent follow- up evaluation, five of 29 patients (18%) who received ABVD alone and nine of 30 (30%) who received ABVD and RT reported persistent mild pulmonary symptoms (P = .36), which did not significantly affect normal daily activity. CONCLUSION: ABVD chemotherapy induced acute pulmonary toxicity that required bleomycin dose modification in a substantial number of patients. The addition of RT resulted in a further decrease in FVC; however, this did not significantly affect the functional status of patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Engert, V. Diehl, J. Franklin, A. Lohri, B. Dorken, W.-D. Ludwig, P. Koch, M. Hanel, M. Pfreundschuh, M. Wilhelm, et al. Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study J. Clin. Oncol., September 20, 2009; 27(27): 4548 - 4554. [Abstract] [Full Text] [PDF]

				E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF]

				F. VILLANI, A. BUSIA, M. VILLANI, A. LAFFRANCHI, S. VIVIANI, and V. BONFANTE Cardiopulmonary Response to Exercise in Patients with Different Degrees of Lung Toxicity after Radio-chemotherapy for Hodgkin's Disease Anticancer Res, February 1, 2009; 29(2): 777 - 783. [Abstract] [Full Text] [PDF]

				A. K. Ng, S. Li, D. Neuberg, R. Chi, D. C. Fisher, B. Silver, and P. M. Mauch A prospective study of pulmonary function in Hodgkin's lymphoma patients Ann. Onc., October 1, 2008; 19(10): 1754 - 1758. [Abstract] [Full Text] [PDF]

				M. Sieniawski, T. Reineke, L. Nogova, A. Josting, B. Pfistner, V. Diehl, and A. Engert Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG) Blood, January 1, 2008; 111(1): 71 - 76. [Abstract] [Full Text] [PDF]

				J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008. [Abstract] [Full Text] [PDF]

				E. Boleti and G. Mead ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors Ann. Onc., February 1, 2007; 18(2): 376 - 380. [Abstract] [Full Text] [PDF]

				J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann. Onc., December 1, 2006; 17(12): 1749 - 1760. [Abstract] [Full Text] [PDF]

				E. Brusamolino, A. Baio, E. Orlandi, L. Arcaini, F. Passamonti, V. Griva, W. Casagrande, C. Pascutto, P. Franchini, and M. Lazzarino Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up. Clin. Cancer Res., November 1, 2006; 12(21): 6487 - 6493. [Abstract] [Full Text] [PDF]

				K. Behringer, K. Breuer, T. Reineke, M. May, L. Nogova, B. Klimm, T. Schmitz, L. Wildt, V. Diehl, and A. Engert Secondary Amenorrhea After Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., October 20, 2005; 23(30): 7555 - 7564. [Abstract] [Full Text] [PDF]

				D. J. Straus, C. S. Portlock, J. Qin, J. Myers, A. D. Zelenetz, C. Moskowitz, A. Noy, A. Goy, and J. Yahalom Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood, December 1, 2004; 104(12): 3483 - 3489. [Abstract] [Full Text] [PDF]

				G. P. Canellos, J. Gollub, D. Neuberg, P. Mauch, and L. N. Shulman Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up Ann. Onc., February 1, 2003; 14(2): 268 - 272. [Abstract] [Full Text] [PDF]

				S. Sleijfer Bleomycin-Induced Pneumonitis Chest, August 1, 2001; 120(2): 617 - 624. [Abstract] [Full Text] [PDF]

				A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]

				A. Wirth, M. Chao, J. Corry, C. Laidlaw, K. Yuen, G. Ryan, D. Byram, S. Davis, J. Kiffer, G. Quong, et al. Mantle Irradiation Alone for Clinical Stage I-II Hodgkin's Disease: Long-Term Follow-Up and Analysis of Prognostic Factors in 261 Patients J. Clin. Oncol., January 1, 1999; 17(1): 230 - 230. [Abstract] [Full Text] [PDF]